Gram negative bacterial infections occur frequently - more than 300,000 hospitalized patients develop serious gram negative bacterial infections each year in the US. Mortality of gram negative bacterial serpsis is greater than 10% and exceeds 30% in immunocompressed patients. The failure of conventional therapy has provided an impetus for the development of new adjuvant treatment of gram negative bacterial infections, such as the use of antibodies directed against endotoxin and endotoxin-induced monokines. This book describes the development of these new approaches and their clinical implementations.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Maße
Höhe: 267 mm
Breite: 184 mm
Gewicht
ISBN-13
978-1-879702-04-2 (9781879702042)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
The clinical problem; historical perspective; current epidemiology; clinical presentation and manifestations; definitions and classification; standard therapy of gram negative bacterial infections; structure of endotoxin; overview; outer polysaccharide; core polysaccharide; lipid a; host responses to endotoxin; pathophysiology of gram-negative bacterial infections; immune responses to endotoxin; new treatment modalities; historical perspective; therapeutic endotoxin clearance lipid A analogues; bactericidal/permeability-increasing protein; therapeutic blockade of cytokine responses; antibody immunotherapy of gram-negative bacterial sepsis; new directions.
